AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Propanc Biopharma shares rise 10.96% intraday after submitting Spain patents for resistant cancer and fibrosis treatments.
ByAinvest
Monday, Dec 1, 2025 9:35 am ET1min read
Propanc Biopharma surged 10.96% in intraday trading following the announcement of two provisional patent submissions for novel treatments targeting resistant cancer and fibrosis. The company, in collaboration with Spanish universities, filed for a foreign filing license in Spain, with plans to extend these patents to key global jurisdictions. The fibrosis-related patent marks the first expansion of its lead proenzyme therapy, PRP, into chronic diseases beyond cancer, positioning it as a potential breakthrough in fibrosis treatment. CEO James Nathanielsz highlighted the significance of these developments, emphasizing PRP’s potential to address unmet medical needs without cytotoxic effects. The planned 2026 Phase 1b First-In-Human study to determine PRP’s therapeutic dose further underscores the company’s progress toward clinical validation, fueling investor optimism about its commercial prospects.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet